Johnson & Johnson (UKEX:JNJ)
â‚´ 5947 0 (0%) Market Cap: 14.82 Til Enterprise Value: 15.47 Til PE Ratio: 24.01 PB Ratio: 4.98 GF Score: 84/100

Johnson & Johnson at Citi Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Transcript

Feb 25, 2021 / 03:45PM GMT
Joanne Karen Wuensch
Citigroup Inc. Exchange Research - Research Analyst

Hello, everybody. Thank you for rejoining us. I'm thrilled today that we have moved on to talk about Johnson & Johnson. And we have Jennifer Taubert with us, EVP, Worldwide Chairman of Pharmaceuticals. Jennifer, welcome.

Jennifer L. Taubert
Johnson & Johnson - Executive VP & Worldwide Chairman of Pharmaceuticals

Thank you so much, Joanne. I'm really happy to be here with you today, and hello, everybody. First of all, on behalf of J&J, I hope that you and your families are remaining safe and healthy. I'm really proud to have a chance to chat with you today around -- about our Pharmaceutical business, which delivered really robust, very, very strong growth throughout 2020, exceeding the market growth rates for our ninth consecutive year.

A couple -- few things I'd like to run through with you here today. First, our broadly based growth was across regions, it was across therapeutic areas, and it was across our key brands. And we think that, that's a key indication

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot